Literature DB >> 22742913

Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes.

Danijela Gnjidic1, Sarah N Hilmer, Fiona M Blyth, Vasi Naganathan, Louise Waite, Markus J Seibel, Andrew J McLachlan, Robert G Cumming, David J Handelsman, David G Le Couteur.   

Abstract

OBJECTIVE: This study aimed to determine an optimal discriminating number of concomitant medications associated with geriatric syndromes, functional outcomes, and mortality in community-dwelling older men. STUDY DESIGN AND
SETTING: Older men aged ≥ 70 years (n=1,705), enrolled in the Concord Health and Aging in Men Project were studied. Receiver operating characteristic curve analysis using the Youden Index and the area under the curve was performed to determine discriminating number of medications in relation to each outcome.
RESULTS: The highest value of the Youden Index for frailty was obtained for a cutoff point of 6.5 medications compared with a cutoff of 5.5 for disability and 3.5 for cognitive impairment. For mortality and incident falls, the highest value of Youden Index was obtained for a cutoff of 4.5 medications. For every one increase in number of medications, the adjusted odds ratios were 1.13 (95% confidence interval [CI]=1.06-1.21) for frailty, 1.08 (95% CI=1.00-1.15) for disability, 1.09 (95% CI=1.04-1.15) for mortality, and 1.07 (95% CI=1.03-1.12) for incident falls. There was no association between increasing number of medications and cognitive impairment.
CONCLUSION: The study supports the use of five or more medications in the current definition of polypharmacy to estimate the medication-related adverse effects for frailty, disability, mortality, and falls. Crown
Copyright © 2012. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22742913     DOI: 10.1016/j.jclinepi.2012.02.018

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  303 in total

1.  Determinants of change in polypharmacy status in Switzerland: the population-based CoLaus study.

Authors:  Nazanin Abolhassani; Julien Castioni; Pedro Marques-Vidal; Peter Vollenweider; Gérard Waeber
Journal:  Eur J Clin Pharmacol       Date:  2017-06-21       Impact factor: 2.953

2.  The missing piece: Clinical pharmacists enhancing the interprofessional nephrology clinic model.

Authors:  Chelsea E Hawley; Laura K Triantafylidis; Julie M Paik
Journal:  J Am Pharm Assoc (2003)       Date:  2019-06-21

3.  Prevalence and factors associated with polypharmacy in older people with cancer.

Authors:  Justin P Turner; Sepehr Shakib; Nimit Singhal; Jonathon Hogan-Doran; Robert Prowse; Sally Johns; J Simon Bell
Journal:  Support Care Cancer       Date:  2014-03-02       Impact factor: 3.603

4.  Locations, Circumstances, and Outcomes of Falls in Patients With Glaucoma.

Authors:  Ayodeji E Sotimehin; Andrea V Yonge; Aleksandra Mihailovic; Sheila K West; David S Friedman; Laura N Gitlin; Pradeep Y Ramulu
Journal:  Am J Ophthalmol       Date:  2018-05-09       Impact factor: 5.258

5.  Association Between Functional Impairment and Medication Burden in Adults with Heart Failure.

Authors:  Parag Goyal; Joanna Bryan; Jerard Kneifati-Hayek; Madeline R Sterling; Samprit Banerjee; Mathew S Maurer; Mark S Lachs; Monika M Safford
Journal:  J Am Geriatr Soc       Date:  2018-11-29       Impact factor: 5.562

6.  Body Composition, IGF1 Status, and Physical Functionality in Nonagenarians: Implications for Osteosarcopenia.

Authors:  Eleonora Poggiogalle; Katie E Cherry; L Joseph Su; Sangkyu Kim; Leann Myers; David A Welsh; S Michal Jazwinski; Eric Ravussin
Journal:  J Am Med Dir Assoc       Date:  2018-08-24       Impact factor: 4.669

7.  Motoric Cognitive Risk Syndrome in Polypharmacy.

Authors:  Claudene J George; Joe Verghese
Journal:  J Am Geriatr Soc       Date:  2020-02-24       Impact factor: 5.562

8.  Quality of prescribing in community-dwelling elderly patients in France: an observational study in community pharmacies.

Authors:  E Bourcier; F Mille; V Brunie; V Korb-Savoldelli; C Lafortune; M Buyse; C Fernandez; P Hindlet
Journal:  Int J Clin Pharm       Date:  2017-09-14

Review 9.  The Role of Deprescribing in Older Adults with Chronic Kidney Disease.

Authors:  Laura K Triantafylidis; Chelsea E Hawley; Laura P Perry; Julie M Paik
Journal:  Drugs Aging       Date:  2018-11       Impact factor: 3.923

10.  Geographical differences in the prevalence of chronic polypharmacy in older people: eleven years of the EPIFARM-Elderly Project.

Authors:  Carlotta Franchi; Massimo Cartabia; Paolo Risso; Daniela Mari; Mauro Tettamanti; Alberto Parabiaghi; Luca Pasina; Codjo Djignefa Djade; Ida Fortino; Angela Bortolotti; Luca Merlino; Alessandro Nobili
Journal:  Eur J Clin Pharmacol       Date:  2013-03-28       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.